Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Georg Hess

Georg Hess

MD
University Medical Center Mainz
Emerging options for patients with MCL who relapse after a frontline BTKi 1:46
Emerging options for patients with MCL who relapse after a frontline BTKi
Georg Hess • 20 Oct 2023
The changing role of autoSCT in mantle cell lymphoma: the impact of novel agents 2:37
The changing role of autoSCT in mantle cell lymphoma: the impact of novel agents
Georg Hess • 20 Oct 2023
Indirect comparison of brexu-cel versus SOC in R/R MCL 1:44
Indirect comparison of brexu-cel versus SOC in R/R MCL
Georg Hess • 20 Oct 2023
Recent updates in MCL 1:02
Recent updates in MCL
Georg Hess • 8 Jun 2021
Optimizing treatment of MCL 2:31
Optimizing treatment of MCL
Georg Hess • 8 Jun 2021
Brexucabtagene autoleucel vs SOC for R/R MCL 3:37
Brexucabtagene autoleucel vs SOC for R/R MCL
Georg Hess • 8 Jun 2021
Clinical activity of abemaciclib in patients with R/R MCL 2:55
Clinical activity of abemaciclib in patients with R/R MCL
Georg Hess • 8 Jun 2021
Temsirolimus with BERT for the treatment of relapsed mantle cell and follicular lymphoma 2:11
Temsirolimus with BERT for the treatment of relapsed mantle cell and follicular lymphoma
Georg Hess • 2 Dec 2016
The content of VJHemOnc is intended for healthcare professionals